Home Pharmaceuticals Cyclosporine Market Size, Share & Growth Graph by 2034

Cyclosporine Market Size, Share & Trends Analysis Report By Indication (Transplant Rejection Prophylaxis, Rheumatoid Arthritis, Psoriasis, Autoimmune Myasthenia Gravis, Dry Eye Disease, Other Indication), By Route of Administration (Oral, Parenteral) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Report Code: SRPH58138DR
Last Updated: Apr, 2026
Pages: 160
Author: Dhanashri Bhapakar
Format: PDF, Excel

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Cyclosporine Market Introduction
    2. By Indication
      1. Introduction
        1. Indication By Value
      2. Transplant Rejection Prophylaxis
        1. By Value
      3. Rheumatoid Arthritis
        1. By Value
      4. Psoriasis
        1. By Value
      5. Autoimmune Myasthenia Gravis
        1. By Value
      6. Dry Eye Disease
        1. By Value
      7. Other Indication
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Parenteral
        1. By Value
    1. Introduction
    2. By Indication
      1. Introduction
        1. Indication By Value
      2. Transplant Rejection Prophylaxis
        1. By Value
      3. Rheumatoid Arthritis
        1. By Value
      4. Psoriasis
        1. By Value
      5. Autoimmune Myasthenia Gravis
        1. By Value
      6. Dry Eye Disease
        1. By Value
      7. Other Indication
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Parenteral
        1. By Value
    4. U.S.
      1. By Indication
        1. Introduction
          1. Indication By Value
        2. Transplant Rejection Prophylaxis
          1. By Value
        3. Rheumatoid Arthritis
          1. By Value
        4. Psoriasis
          1. By Value
        5. Autoimmune Myasthenia Gravis
          1. By Value
        6. Dry Eye Disease
          1. By Value
        7. Other Indication
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Parenteral
          1. By Value
    5. Canada
    1. Introduction
    2. By Indication
      1. Introduction
        1. Indication By Value
      2. Transplant Rejection Prophylaxis
        1. By Value
      3. Rheumatoid Arthritis
        1. By Value
      4. Psoriasis
        1. By Value
      5. Autoimmune Myasthenia Gravis
        1. By Value
      6. Dry Eye Disease
        1. By Value
      7. Other Indication
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Parenteral
        1. By Value
    4. U.K.
      1. By Indication
        1. Introduction
          1. Indication By Value
        2. Transplant Rejection Prophylaxis
          1. By Value
        3. Rheumatoid Arthritis
          1. By Value
        4. Psoriasis
          1. By Value
        5. Autoimmune Myasthenia Gravis
          1. By Value
        6. Dry Eye Disease
          1. By Value
        7. Other Indication
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Parenteral
          1. By Value
    5. Germany
    6. France
    7. Spain
    8. Italy
    9. Russia
    10. Nordic
    11. Benelux
    12. Rest of Europe
    1. Introduction
    2. By Indication
      1. Introduction
        1. Indication By Value
      2. Transplant Rejection Prophylaxis
        1. By Value
      3. Rheumatoid Arthritis
        1. By Value
      4. Psoriasis
        1. By Value
      5. Autoimmune Myasthenia Gravis
        1. By Value
      6. Dry Eye Disease
        1. By Value
      7. Other Indication
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Parenteral
        1. By Value
    4. China
      1. By Indication
        1. Introduction
          1. Indication By Value
        2. Transplant Rejection Prophylaxis
          1. By Value
        3. Rheumatoid Arthritis
          1. By Value
        4. Psoriasis
          1. By Value
        5. Autoimmune Myasthenia Gravis
          1. By Value
        6. Dry Eye Disease
          1. By Value
        7. Other Indication
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Parenteral
          1. By Value
    5. Korea
    6. Japan
    7. India
    8. Australia
    9. Taiwan
    10. South East Asia
    11. Rest of Asia-Pacific
    1. Introduction
    2. By Indication
      1. Introduction
        1. Indication By Value
      2. Transplant Rejection Prophylaxis
        1. By Value
      3. Rheumatoid Arthritis
        1. By Value
      4. Psoriasis
        1. By Value
      5. Autoimmune Myasthenia Gravis
        1. By Value
      6. Dry Eye Disease
        1. By Value
      7. Other Indication
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Parenteral
        1. By Value
    4. UAE
      1. By Indication
        1. Introduction
          1. Indication By Value
        2. Transplant Rejection Prophylaxis
          1. By Value
        3. Rheumatoid Arthritis
          1. By Value
        4. Psoriasis
          1. By Value
        5. Autoimmune Myasthenia Gravis
          1. By Value
        6. Dry Eye Disease
          1. By Value
        7. Other Indication
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Parenteral
          1. By Value
    5. Turkey
    6. Saudi Arabia
    7. South Africa
    8. Egypt
    9. Nigeria
    10. Rest of MEA
    1. Introduction
    2. By Indication
      1. Introduction
        1. Indication By Value
      2. Transplant Rejection Prophylaxis
        1. By Value
      3. Rheumatoid Arthritis
        1. By Value
      4. Psoriasis
        1. By Value
      5. Autoimmune Myasthenia Gravis
        1. By Value
      6. Dry Eye Disease
        1. By Value
      7. Other Indication
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Parenteral
        1. By Value
    4. Brazil
      1. By Indication
        1. Introduction
          1. Indication By Value
        2. Transplant Rejection Prophylaxis
          1. By Value
        3. Rheumatoid Arthritis
          1. By Value
        4. Psoriasis
          1. By Value
        5. Autoimmune Myasthenia Gravis
          1. By Value
        6. Dry Eye Disease
          1. By Value
        7. Other Indication
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Parenteral
          1. By Value
    5. Mexico
    6. Argentina
    7. Chile
    8. Colombia
    9. Rest of LATAM
    1. Cyclosporine Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. AbbVie Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Strides Pharma Science Limited
    3. Apotex Inc.
    4. EonLabs
    5. Mayne Pharma Group Limited
    6. Intas Pharmaceuticals Ltd.
    7. Novartis AG
    8. Santen Pharmaceutical Co., Ltd.
    9. Sun Pharmaceutical Industries Ltd.
    10. Teva Pharmaceutical Industries Ltd.
    11. Viatris Inc.
    12. Cipla Ltd.
    13. Reddy’s Laboratories Ltd.
    14. Glenmark Pharmaceuticals Ltd.
    15. Pfizer Inc.
    16. Astellas Pharma Inc.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer
Get This Report

Download Free Sample

Our Clients:

LG Electronics
AMCAD Engineering
KOBE STEEL LTD.
Hindustan National Glass & Industries Limited
Voith Group
International Paper
Hansol Paper
Whirlpool Corporation
Sony
Samsung Electronics
Qualcomm
Google
Fiserv
Veto-Pharma
Nippon Becton Dickinson
Merck
Argon Medical Devices
Abbott
Ajinomoto
Denon
Doosan
Meiji Seika Kaisha Ltd
LG Chemicals
LCY chemical group
Bayer
Airrane
BASF
Toyota Industries
Nissan Motors
Neenah
Mitsubishi
Hyundai Motor Company

We are featured on:

WhatsApp
Chat with us on WhatsApp
Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.